BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Small Cell Lung Cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Clinical Outcome
29 results:

  • 1. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
    Liu X; Deng J; Zhang R; Xing J; Wu Y; Chen W; Liang B; Xing D; Xu J; Zhang M
    Front Immunol; 2023; 14():1335252. PubMed ID: 38162667
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Genomic Characteristics and the Potential clinical Implications in Oligometastatic Non-small cell lung cancer.
    Liao R; Chen K; Li J; He H; Yi G; Huang M; Chen R; Shen L; Zhang X; Xu Z; Yang Z; Peng Y
    Cancer Res Treat; 2023 Jul; 55(3):814-831. PubMed ID: 36634615
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma.
    Chen S; Fu A; Lu Y; Lu W; Chen Y; Hong S; Zhou S; Xiang T; Zhang Z; Cai Y
    BMC Genomics; 2022 Jan; 23(1):55. PubMed ID: 35031014
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
    Couraud S; Barlesi F; Fontaine-Deraluelle C; Debieuvre D; Merlio JP; Moreau L; Beau-Faller M; Veillon R; Mosser J; Al Freijat F; Bringuier PP; Léna H; Ouafik L; Westeel V; Morel A; Audigier-Valette C; Missy P; Langlais A; Morin F; Souquet PJ; Planchard D;
    Eur J Cancer; 2019 Jul; 116():86-97. PubMed ID: 31181537
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-small cell lung cancer.
    Fang W; Ma Y; Yin JC; Hong S; Zhou H; Wang A; Wang F; Bao H; Wu X; Yang Y; Huang Y; Zhao H; Shao YW; Zhang L
    Clin Cancer Res; 2019 Aug; 25(16):5015-5026. PubMed ID: 31085721
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Early Noninvasive Detection of Response to Targeted Therapy in Non-small cell lung cancer.
    Phallen J; Leal A; Woodward BD; Forde PM; Naidoo J; Marrone KA; Brahmer JR; Fiksel J; Medina JE; Cristiano S; Palsgrove DN; Gocke CD; Bruhm DC; Keshavarzian P; Adleff V; Weihe E; Anagnostou V; Scharpf RB; Velculescu VE; Husain H
    Cancer Res; 2019 Mar; 79(6):1204-1213. PubMed ID: 30573519
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
    Oh YJ; Park SY; Seo YH
    Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.
    Koinis F; Voutsina A; Kalikaki A; Koutsopoulos A; Lagoudaki E; Tsakalaki E; Dermitzaki EK; Kontopodis E; Pallis AG; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2018 Feb; 20(2):140-149. PubMed ID: 28631135
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Significance of EGFR signaling pathway genetic alterations in radically resected non-small cell lung cancers from a Polish cohort. One institutional study.
    Kowalczuk O; Kozlowski M; Milewski R; Minarowski L; Reszec J
    Adv Med Sci; 2015 Sep; 60(2):277-86. PubMed ID: 26118982
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC).
    Bellezza G; Del Sordo R; Colella R; Ludovini V; Ragusa M; Bianconi F; Ferri I; Borri F; Chiari R; Puma F; Crinò L; Sidoni A
    Virchows Arch; 2013 Nov; 463(5):663-71. PubMed ID: 24013863
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. p130Cas is an essential transducer element in erbb2 transformation.
    Cabodi S; Tinnirello A; Bisaro B; Tornillo G; del Pilar Camacho-Leal M; Forni G; Cojoca R; Iezzi M; Amici A; Montani M; Eva A; Di Stefano P; Muthuswamy SK; Tarone G; Turco E; Defilippi P
    FASEB J; 2010 Oct; 24(10):3796-808. PubMed ID: 20505116
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Correlation of epidermal growth factor receptor mutations and her2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
    Han Y; Xu JM; Duan HQ; Zhang Y; Liu XQ; Zhang JS
    Chin J Cancer; 2010 Jan; 29(1):69-75. PubMed ID: 20038315
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. EGFR mutations and her2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
    Xu JM; Han Y; Duan HQ; Gao EM; Zhang Y; Liu XQ; Zhang JS; Toschi L; Galetta D; Azzariti A; Paradiso A
    J Cancer Res Clin Oncol; 2009 Jun; 135(6):771-82. PubMed ID: 19020901
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Steroid receptor and growth factor receptor expression in human nonsmall cell lung cancers using cells procured by laser-capture microdissection.
    Kerr A; Eliason JF; Wittliff JL
    Adv Exp Med Biol; 2008; 617():377-84. PubMed ID: 18497061
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.
    Tsao AS; Tang XM; Sabloff B; Xiao L; Shigematsu H; Roth J; Spitz M; Hong WK; Gazdar A; Wistuba I
    J Thorac Oncol; 2006 Mar; 1(3):231-9. PubMed ID: 17409862
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
    Endo K; Sasaki H; Yano M; Kobayashi Y; Yukiue H; Haneda H; Suzuki E; Kawano O; Fujii Y
    Oncol Rep; 2006 Sep; 16(3):533-41. PubMed ID: 16865253
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
    Calvo E; Baselga J
    J Clin Oncol; 2006 May; 24(14):2158-63. PubMed ID: 16682734
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.
    Kuo T; Fisher GA
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S62-70. PubMed ID: 16336751
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.